히스톤 탈아세틸화 효소 억제제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 연평균 7.9%의 CAGR로 17억 7,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 생명공학에 대한 투자 확대, 노인 인구 증가, 유리한 규제 승인 및 의약품 승인 절차의 신속화, 약물전달 시스템 개선, 치료용도 확대 등에 기인하는 것으로 보입니다. 예측 기간 동안 주요 동향으로는 환자 건강 모니터링을 위한 웨어러블 기기의 통합, 나노기술과 약물전달 방법의 혁신, 바이오마커 식별 및 검증의 발전, 인공지능(AI)과 머신러닝, 차세대 시퀀싱 등 다양한 기술들이 등장할 것으로 예상됩니다.
암 발병률의 증가는 히스톤 탈아세틸화 효소 억제제 시장의 성장을 견인할 것으로 예상됩니다. 이러한 암 환자 증가는 인구 고령화, 담배, 식습관, 환경오염물질 등의 위험 요인에 대한 노출 증가, 조기 및 빈번한 발견으로 이어지는 진단 기술의 발전 등의 요인에 기인합니다. 히스톤 탈아세틸화효소 억제제는 크로마틴 구조를 변화시켜 암을 치료하고, 암 억제 유전자를 활성화하고, 암 유전자를 억제하여 암세포의 세포주기 정지 및 세포사멸을 유발합니다. 예를 들어, 2024년 2월 세계보건기구(WHO)는 2050년에는 약 3,500만 명의 암 환자가 새로 발생하여 2022년 추정치인 2,000만 명에서 77% 증가할 것으로 예측했습니다. 이처럼 암 발병률의 증가는 히스톤 탈아세틸화효소 억제제 시장을 견인하고 있습니다.
히스톤 탈아세틸화효소 억제제 시장의 주요 기업들은 더 많은 치료 옵션을 제공하고 환자의 편의성과 순응도를 높이기 위해 경구용 히스톤 탈아세틸화효소(HDAC) 억제제와 같은 혁신적인 제제 개발에 주력하고 있습니다. 경구용 HDAC 억제제는 유전자 조절에 관여하는 HDAC 효소를 표적으로 하는 경구용 약물로, 암 및 염증성 질환을 포함한 다양한 질환의 치료에 사용할 수 있습니다. 예를 들어, 2024년 3월 이탈리아 제약사 Italfarmaco S.p.A.는 경구용 HDAC 억제제인 듀비자트(dubizat, 지비노스타트)에 대해 6세 이상 Duchenne muscular dystrophy(DMD) 환자의 치료제로 FDA의 승인을 받았습니다. 듀비자트는 염증과 섬유화를 억제하여 근육 손상을 완화하고, 동시에 근육 섬유의 재생을 촉진하여 DMD에 따른 근력저하 진행을 지연시킵니다. 이번 승인은 매우 중요한 3상 시험인 EPIDYS 시험에 근거한 것으로, 듀비자트 투여군은 위약 투여군 대비 통계적으로 유의미하게 4단 계단 오르내리기를 완료하는 데 걸리는 시간이 단축되었습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 신종 코로나바이러스 감염증, 그리고 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 히스톤 탈아세틸화효소 억제제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업 분석
- 세계의 히스톤 탈아세틸화효소 억제제 시장 : 성장률 분석
- 세계의 히스톤 탈아세틸화효소 억제제 시장 실적 : 규모와 성장, 2019-2024
- 세계의 히스톤 탈아세틸화효소 억제제 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 히스톤 탈아세틸화효소 억제제 전체 시장(TAM)
제6장 시장 세분화
- 세계의 히스톤 탈아세틸화효소 억제제 시장 분류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 클래스 I 히스톤 탈아세틸화효소(HDAC)
- 클래스 II 히스톤 탈아세틸화효소(HDAC)
- 클래스 III 히스톤 탈아세틸화효소(HDAC)
- 기타 분류
- 세계의 히스톤 탈아세틸화효소 억제제 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 경구
- 주사제
- 기타 투여 경로
- 세계의 히스톤 탈아세틸화효소 억제제 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원 약국
- 온라인 약국
- 소매 약국
- 기타 유통 채널
- 세계의 히스톤 탈아세틸화효소 억제제 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 종양학
- 신경학
- 기타 용도
- 세계의 히스톤 탈아세틸화효소 억제제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원
- 홈케어
- 전문 클리닉
- 기타 최종사용자
- 세계의 히스톤 탈아세틸화효소 억제제 시장, 클래스 I 히스톤 탈아세틸화효소(HDAC) 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- HDAC1 억제제
- HDAC2 억제제
- HDAC3 억제제
- HDAC8 억제제
- 세계의 히스톤 탈아세틸화효소 억제제 시장, 클래스 II 히스톤 탈아세틸화효소(HDAC) 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- HDAC4 억제제
- HDAC5 억제제
- HDAC6 억제제
- HDAC7 억제제
- HDAC9 억제제
- HDAC10 억제제
- 세계의 히스톤 탈아세틸화효소 억제제 시장, 클래스 III 히스톤 탈아세틸화효소(HDAC) 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 시트루인 1(SIRT1) 억제제
- 시트루인 2(SIRT2) 억제제
- 시트루인 3(SIRT3) 억제제
- 시트루인 4(SIRT4) 억제제
- 시트루인 5(SIRT5) 억제제
- 시트루인 6(SIRT6) 억제제
- 시트루인 7(SIRT7) 억제제
- 세계의 히스톤 탈아세틸화효소 억제제 시장, 기타 분류 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 이중 작용 HDAC 억제제
- 범HDAC 억제제
- 선택적 HDAC 억제제
- 복합 억제제(HDAC+기타 메커니즘)
제7장 지역별·국가별 분석
- 세계의 히스톤 탈아세틸화효소 억제제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 히스톤 탈아세틸화효소 억제제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 히스톤 탈아세틸화효소 억제제 시장 : 경쟁 구도
- 히스톤 탈아세틸화효소 억제제 시장 : 기업 개요
- Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
- Aurobindo Pharma Limited Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
- Karyopharm Therapeutics Inc.
- Syndax Pharmaceuticals Inc.
- MEI Pharma Inc.
- Italfarmaco S.p.A.
- Tokyo Chemical Industry Co. Ltd.
- InvivoGen Corp.
- Huya Bioscience International LLC
- Crystal Genomics Inc.
- Spectrum Pharmaceuticals Inc.
- Curis Inc.
- Celgene Corporation
- Celleron Therapeutics
- Medivir AB
- Onxeo SA
- Regenacy Pharmaceuticals Inc
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 히스톤 탈아세틸화효소 억제제 시장 2029 : 새로운 기회를 제공하는 국가
- 히스톤 탈아세틸화효소 억제제 시장 2029 : 새로운 기회를 제공하는 부문
- 히스톤 탈아세틸화효소 억제제 시장 2029 : 성장 전략
제36장 부록
ksm
Histone deacetylase inhibitors are compounds that disrupt the function of histone deacetylases, which are enzymes responsible for removing acetyl groups from histone proteins. This disruption can lead to increased acetylation of histones, resulting in a more relaxed chromatin structure and changes in gene expression.
Histone deacetylase inhibitors are mainly classified into Class I, Class II, Class III, and other types. Histone deacetylases are a group of enzymes that remove acetyl groups from histone proteins, causing chromatin condensation and transcriptional repression. These inhibitors can be administered orally, via injection, and are available through hospital pharmacies, online pharmacies, retail pharmacies, among others. They are useful in various fields such as oncology and neurology, with end users including hospitals, home care settings, specialty clinics, and other facilities.
The histone deacetylase inhibitors market research report is one of a series of new reports from The Business Research Company that provides histone deacetylase inhibitors with a histone deacetylase inhibitors market share, detailed histone deacetylase inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the histone deacetylase inhibitors industry. This histone deacetylase inhibitors market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The histone deacetylase inhibitors market size has grown strongly in recent years. It will grow from $1.2 billion in 2024 to $1.3 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to regulatory support and fast-track approvals, the growing prevalence of cancer, increased funding for cancer research, the expansion of therapeutic applications, and increased expenditure on healthcare infrastructure.
The histone deacetylase inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.77 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to growing investment in biotechnology, the growing elderly population, favorable regulatory approvals and faster drug approval processes, improved drug delivery systems, and the expansion of therapeutic applications. Major trends in the forecast period include the integration of wearable devices to monitor patient health, innovations in nanotechnology and drug delivery methods, advances in identifying and validating biomarkers, artificial intelligence (AI) and machine learning, and next-generation sequencing.
The rising incidence of cancer is expected to drive the growth of the histone deacetylase inhibitors market. This increase in cancer cases is largely due to factors such as aging populations, higher exposure to risk factors such as tobacco, diet, and environmental pollutants, and advancements in diagnostic techniques that lead to earlier and more frequent detection. Histone deacetylase inhibitors treat cancer by altering chromatin structure, which activates tumor suppressor genes and suppresses oncogenes, causing cell cycle arrest and apoptosis in cancer cells. For example, in February 2024, the World Health Organization predicted that approximately 35 million new cancer cases would occur in 2050, a 77% increase from the estimated 20 million cases in 2022. Thus, the growing incidence of cancer is boosting the histone deacetylase inhibitors market.
Major companies in the histone deacetylase inhibitors market are focusing on developing innovative product formulations, such as oral histone deacetylase (HDAC) inhibitors, to provide more treatment options and enhance patient convenience and compliance. An oral HDAC inhibitor is a drug taken by mouth that targets HDAC enzymes involved in gene regulation and can be used to treat various diseases, including cancer and inflammatory conditions. For instance, in March 2024, Italfarmaco S.p.A., an Italian pharmaceutical company, received FDA approval for Duvyzat (givinostat), an oral HDAC inhibitor, for treating Duchenne muscular dystrophy (DMD) in patients aged 6 years and older. Duvyzat mitigates muscle damage by reducing inflammation and fibrosis while promoting muscle fiber regeneration, slowing the progression of muscle deterioration associated with DMD. This approval was based on the pivotal phase 3 EPIDYS trial, which showed that patients on Duvyzat had a statistically significant decrease in the time to complete the four-stair climb assessment compared to placebo.
In January 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Mirati Therapeutics Inc. for an undisclosed amount. This acquisition aims to significantly strengthen and diversify Bristol Myers' oncology portfolio, which includes the lung cancer medicine KRAZATI (adagrasib) and a leading KRAS and KRAS-enabling program with two Phase 1 candidates. The goal is to accelerate the development and delivery of innovative cancer treatments and enhance Bristol Myers' long-term growth in oncology. Mirati Therapeutics Inc. is a US-based targeted oncology company specializing in developing cancer therapeutics and histone deacetylase inhibitors.
Major companies operating in the histone deacetylase inhibitors market are Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Aurobindo Pharma Limited, Karyopharm Therapeutics Inc., Syndax Pharmaceuticals Inc., MEI Pharma Inc., Italfarmaco S.p.A., Tokyo Chemical Industry Co. Ltd., InvivoGen Corp., Huya Bioscience International LLC, Crystal Genomics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Celgene Corporation, Celleron Therapeutics, Medivir AB, Onxeo SA, Regenacy Pharmaceuticals Inc., Shenzhen Chipscreen Biosciences Co. Ltd., Wellness Pharma International LLC, Forum Pharmaceuticals Inc., Midatech Pharma PLC
North America was the largest region in the histone deacetylase inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the histone deacetylase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The histone deacetylase inhibitors market consists of sales of bioinformatics tools, cell culture systems, laboratory equipment, and diagnostic devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Histone Deacetylase Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on histone deacetylase inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for histone deacetylase inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The histone deacetylase inhibitors market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Classification: Class I Histone Deacetylases (HDACs); Class II Histone Deacetylases (HDACs); Class III Histone Deacetylases (HDACs); Other Classifications
- 2) By Route Of Administration: Oral; Injectable; Other Routes Of Administration
- 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels
- 4) By Application: Oncology; Neurology; Other Applications
- 5) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
- Suubsegments:
- 1) By Class I Histone Deacetylases (HDACs): HDAC1 Inhibitors; HDAC2 Inhibitors; HDAC3 Inhibitors; HDAC8 Inhibitors
- 2) By Class II Histone Deacetylases (HDACs): HDAC4 Inhibitors; HDAC5 Inhibitors; HDAC6 Inhibitors; HDAC7 Inhibitors; HDAC9 Inhibitors; HDAC10 Inhibitors
- 3) By Class III Histone Deacetylases (HDACs): Sirtuin 1 (SIRT1) Inhibitors; Sirtuin 2 (SIRT2) Inhibitors; Sirtuin 3 (SIRT3) Inhibitors; Sirtuin 4 (SIRT4) Inhibitors; Sirtuin 5 (SIRT5) Inhibitors; Sirtuin 6 (SIRT6) Inhibitors; Sirtuin 7 (SIRT7) Inhibitors
- 4) By Other Classifications: Dual-acting HDAC Inhibitors; Pan-HDAC Inhibitors; Selective HDAC Inhibitors; Combination Inhibitors (HDAC + Other Mechanisms)
- Companies Mentioned: Merck & Co. Inc.; AstraZeneca plc; Novartis AG; Eisai Co. Ltd.; Aurobindo Pharma Limited
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Histone Deacetylase Inhibitors Market Characteristics
3. Histone Deacetylase Inhibitors Market Trends And Strategies
4. Histone Deacetylase Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Histone Deacetylase Inhibitors Growth Analysis And Strategic Analysis Framework
- 5.1. Global Histone Deacetylase Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Histone Deacetylase Inhibitors Market Growth Rate Analysis
- 5.4. Global Histone Deacetylase Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Histone Deacetylase Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Histone Deacetylase Inhibitors Total Addressable Market (TAM)
6. Histone Deacetylase Inhibitors Market Segmentation
- 6.1. Global Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Class I Histone Deacetylases (HDACs)
- Class II Histone Deacetylases (HDACs)
- Class III Histone Deacetylases (HDACs)
- Other Classifications
- 6.2. Global Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Injectable
- Other Routes Of Administration
- 6.3. Global Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Other Distribution Channels
- 6.4. Global Histone Deacetylase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oncology
- Neurology
- Other Applications
- 6.5. Global Histone Deacetylase Inhibitors Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Homecare
- Specialty Clinics
- Other End Users
- 6.6. Global Histone Deacetylase Inhibitors Market, Sub-Segmentation Of Class I Histone Deacetylases (HDACs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- HDAC1 Inhibitors
- HDAC2 Inhibitors
- HDAC3 Inhibitors
- HDAC8 Inhibitors
- 6.7. Global Histone Deacetylase Inhibitors Market, Sub-Segmentation Of Class II Histone Deacetylases (HDACs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- HDAC4 Inhibitors
- HDAC5 Inhibitors
- HDAC6 Inhibitors
- HDAC7 Inhibitors
- HDAC9 Inhibitors
- HDAC10 Inhibitors
- 6.8. Global Histone Deacetylase Inhibitors Market, Sub-Segmentation Of Class III Histone Deacetylases (HDACs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Sirtuin 1 (SIRT1) Inhibitors
- Sirtuin 2 (SIRT2) Inhibitors
- Sirtuin 3 (SIRT3) Inhibitors
- Sirtuin 4 (SIRT4) Inhibitors
- Sirtuin 5 (SIRT5) Inhibitors
- Sirtuin 6 (SIRT6) Inhibitors
- Sirtuin 7 (SIRT7) Inhibitors
- 6.9. Global Histone Deacetylase Inhibitors Market, Sub-Segmentation Of Other Classifications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Dual-acting HDAC Inhibitors
- Pan-HDAC Inhibitors
- Selective HDAC Inhibitors
- Combination Inhibitors (HDAC + Other Mechanisms)
7. Histone Deacetylase Inhibitors Market Regional And Country Analysis
- 7.1. Global Histone Deacetylase Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Histone Deacetylase Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Histone Deacetylase Inhibitors Market
- 8.1. Asia-Pacific Histone Deacetylase Inhibitors Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Histone Deacetylase Inhibitors Market
- 9.1. China Histone Deacetylase Inhibitors Market Overview
- 9.2. China Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Histone Deacetylase Inhibitors Market
- 10.1. India Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Histone Deacetylase Inhibitors Market
- 11.1. Japan Histone Deacetylase Inhibitors Market Overview
- 11.2. Japan Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Histone Deacetylase Inhibitors Market
- 12.1. Australia Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Histone Deacetylase Inhibitors Market
- 13.1. Indonesia Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Histone Deacetylase Inhibitors Market
- 14.1. South Korea Histone Deacetylase Inhibitors Market Overview
- 14.2. South Korea Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Histone Deacetylase Inhibitors Market
- 15.1. Western Europe Histone Deacetylase Inhibitors Market Overview
- 15.2. Western Europe Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Histone Deacetylase Inhibitors Market
- 16.1. UK Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Histone Deacetylase Inhibitors Market
- 17.1. Germany Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Histone Deacetylase Inhibitors Market
- 18.1. France Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Histone Deacetylase Inhibitors Market
- 19.1. Italy Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Histone Deacetylase Inhibitors Market
- 20.1. Spain Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Histone Deacetylase Inhibitors Market
- 21.1. Eastern Europe Histone Deacetylase Inhibitors Market Overview
- 21.2. Eastern Europe Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Histone Deacetylase Inhibitors Market
- 22.1. Russia Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Histone Deacetylase Inhibitors Market
- 23.1. North America Histone Deacetylase Inhibitors Market Overview
- 23.2. North America Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Histone Deacetylase Inhibitors Market
- 24.1. USA Histone Deacetylase Inhibitors Market Overview
- 24.2. USA Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Histone Deacetylase Inhibitors Market
- 25.1. Canada Histone Deacetylase Inhibitors Market Overview
- 25.2. Canada Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Histone Deacetylase Inhibitors Market
- 26.1. South America Histone Deacetylase Inhibitors Market Overview
- 26.2. South America Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Histone Deacetylase Inhibitors Market
- 27.1. Brazil Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Histone Deacetylase Inhibitors Market
- 28.1. Middle East Histone Deacetylase Inhibitors Market Overview
- 28.2. Middle East Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Histone Deacetylase Inhibitors Market
- 29.1. Africa Histone Deacetylase Inhibitors Market Overview
- 29.2. Africa Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Histone Deacetylase Inhibitors Market Competitive Landscape And Company Profiles
- 30.1. Histone Deacetylase Inhibitors Market Competitive Landscape
- 30.2. Histone Deacetylase Inhibitors Market Company Profiles
- 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Aurobindo Pharma Limited Overview, Products and Services, Strategy and Financial Analysis
31. Histone Deacetylase Inhibitors Market Other Major And Innovative Companies
- 31.1. Karyopharm Therapeutics Inc.
- 31.2. Syndax Pharmaceuticals Inc.
- 31.3. MEI Pharma Inc.
- 31.4. Italfarmaco S.p.A.
- 31.5. Tokyo Chemical Industry Co. Ltd.
- 31.6. InvivoGen Corp.
- 31.7. Huya Bioscience International LLC
- 31.8. Crystal Genomics Inc.
- 31.9. Spectrum Pharmaceuticals Inc.
- 31.10. Curis Inc.
- 31.11. Celgene Corporation
- 31.12. Celleron Therapeutics
- 31.13. Medivir AB
- 31.14. Onxeo SA
- 31.15. Regenacy Pharmaceuticals Inc
32. Global Histone Deacetylase Inhibitors Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Histone Deacetylase Inhibitors Market
34. Recent Developments In The Histone Deacetylase Inhibitors Market
35. Histone Deacetylase Inhibitors Market High Potential Countries, Segments and Strategies
- 35.1 Histone Deacetylase Inhibitors Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Histone Deacetylase Inhibitors Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Histone Deacetylase Inhibitors Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
